Subject: To understand the perception of inositols in the management of PCOS based on patient profile
Polycystic ovarian syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age, affecting approximately 3.7 - 22.5% of them. It is a major cause of menstrual disturbances, hirsutism, and female anovulatory infertility. Current evidence suggests that insulin resistance and compensatory hyperinsulinemia are a central feature of PCOS. Although the insulin resistance is thought to be fundamental for PCOS, obesity tends to worsen it and the accompanying metabolic disturbance. While the dominant action occurs through the insulin receptor tyrosine kinase and its primary tyrosine phosphorylated substrates second messengers, inositol glycans also mediate many metabolic actions of insulin. Myoinositol (Ml) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. Combination inositol therapy (Ml and DCI) has the potential to improve all symptoms, signs, and laboratory anomalies of PCOS.
We have planned to conduct a survey to understand the perception of inositols in the management of PCOS based on patient profile.
If you agree to participate, we request you to provide us a copy of relevant information in the standard data collection forms (which we call DCF). You will be responsible for verifying the DCF to ensure that the DCF signed by you are free from errors or omissions.
We trust you and we are partners in ensuring safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply document along with your visiting card for accuracy of records.
|
}}){kind=logo}